Next, we examined whether METTL1 expression levels helped to define patients with PTEN-loss-associated decreased survival, which is of clinical relevance, and distinguish indolent from aggressive disease in patients with clinically localised tumours [47]. Here, METTL1 is linked to neoplasm.